A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 25 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2025.
- 25 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2025.
- 13 Apr 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.